GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immuneering Corp (NAS:IMRX) » Definitions » ROE %

Immuneering (Immuneering) ROE % : -67.61% (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Immuneering ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Immuneering's annualized net income for the quarter that ended in Mar. 2024 was $-57.23 Mil. Immuneering's average Total Stockholders Equity over the quarter that ended in Mar. 2024 was $84.65 Mil. Therefore, Immuneering's annualized ROE % for the quarter that ended in Mar. 2024 was -67.61%.

The historical rank and industry rank for Immuneering's ROE % or its related term are showing as below:

IMRX' s ROE % Range Over the Past 10 Years
Min: -55.71   Med: -50.24   Max: -38
Current: -55.71

During the past 5 years, Immuneering's highest ROE % was -38.00%. The lowest was -55.71%. And the median was -50.24%.

IMRX's ROE % is ranked worse than
57.65% of 1360 companies
in the Biotechnology industry
Industry Median: -44.015 vs IMRX: -55.71

Immuneering ROE % Historical Data

The historical data trend for Immuneering's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immuneering ROE % Chart

Immuneering Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
ROE %
- - -50.24 -38.00 -53.36

Immuneering Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -52.41 -45.80 -45.98 -62.01 -67.61

Competitive Comparison of Immuneering's ROE %

For the Biotechnology subindustry, Immuneering's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Immuneering's ROE % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Immuneering's ROE % distribution charts can be found below:

* The bar in red indicates where Immuneering's ROE % falls into.



Immuneering ROE % Calculation

Immuneering's annualized ROE % for the fiscal year that ended in Dec. 2023 is calculated as

ROE %=Net Income (A: Dec. 2023 )/( (Total Stockholders Equity (A: Dec. 2022 )+Total Stockholders Equity (A: Dec. 2023 ))/ count )
=-53.472/( (109.85+90.576)/ 2 )
=-53.472/100.213
=-53.36 %

Immuneering's annualized ROE % for the quarter that ended in Mar. 2024 is calculated as

ROE %=Net Income (Q: Mar. 2024 )/( (Total Stockholders Equity (Q: Dec. 2023 )+Total Stockholders Equity (Q: Mar. 2024 ))/ count )
=-57.232/( (90.576+78.723)/ 2 )
=-57.232/84.6495
=-67.61 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Mar. 2024) net income data. ROE % is displayed in the 30-year financial page.


Immuneering  (NAS:IMRX) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Mar. 2024 )
=Net Income/Total Stockholders Equity
=-57.232/84.6495
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-57.232 / 0)*(0 / 95.284)*(95.284 / 84.6495)
=Net Margin %*Asset Turnover*Equity Multiplier
=N/A %*0*1.1256
=ROA %*Equity Multiplier
=N/A %*1.1256
=-67.61 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Mar. 2024 )
=Net Income/Total Stockholders Equity
=-57.232/84.6495
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-57.232 / -57.232) * (-57.232 / -61.304) * (-61.304 / 0) * (0 / 95.284) * (95.284 / 84.6495)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 1 * 0.9336 * N/A % * 0 * 1.1256
=-67.61 %

Note: The net income data used here is four times the quarterly (Mar. 2024) net income data. The Revenue data used here is four times the quarterly (Mar. 2024) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Immuneering ROE % Related Terms

Thank you for viewing the detailed overview of Immuneering's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Immuneering (Immuneering) Business Description

Traded in Other Exchanges
N/A
Address
245 Main Street, Second Floor, Cambridge, MA, USA, 02142
Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to leading pharmaceutical and biotechnology companies.
Executives
Cormorant Asset Management, Lp 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Bihua Chen 10 percent owner C/O CORMORANT ASSET MANAGEMENT, LP, 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Cormorant Global Healthcare Master Fund, Lp 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Cormorant Private Healthcare Fund Iii Lp 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Harold Eugene Brakewood officer: Chief Business Officer C/O IMMUNEERING CORPORATION, 245 MAIN STREET, SECOND FLOOR, CAMBRIDGE MA 02142
Leah R Neufeld officer: Chief People Officer C/O IMMUNEERING CORPORATION, 245 MAIN STREET, SECOND FLOOR, CAMBRIDGE MA 02142
Mallory Morales officer: Vice President, Finance C/O IMMUNEERING CORPORATION, 245 MAIN STREET, SECOND FLOOR, CAMBRIDGE MA 02142
Brett Matthew Hall officer: Chief Scientific Officer C/O IMMUNEERING CORPORATION, 245 MAIN STREET, SECOND FLOOR, CAMBRIDGE MA 02142
Michael Bookman officer: General Counsel and Secretary C/O FREQUENCY THERAPEUTICS, INC., 10 PRESIDENTIAL WAY, 2ND FLOOR, WOBURN MA 01801
Laurie Keating director 300 THIRD STREET, CAMBRIDGE MA 02142
Biren Amin officer: CFO, Treasurer C/O IMMUNEERING CORPORATION, 245 MAIN STREET, SECOND FLOOR, CAMBRIDGE MA 02142
Benjamin J. Zeskind director, 10 percent owner, officer: President and CEO C/O IMMUNEERING CORPORATION, 245 MAIN STREET, SECOND FLOOR, CAMBRIDGE MA 02142
Scott Barrett officer: Chief Medical Officer C/O IMMUNEERING CORPORATION, 245 MAIN STREET, SECOND FLOOR, CAMBRIDGE MA 02142
Peter Feinberg director C/O IMMUNEERING CORPORATION, 245 MAIN STREET, SECOND FLOOR, CAMBRIDGE MA 02142
Ann E Berman director 255 STATE STREET, BOSTON MA 02109